Boehringer's Ofev wins green light in Europe; Wales grants access to Ariad's Iclusig;

> SCIO Health Analytics has picked up Data Intelligence, a business intelligence and analytics provider to the pharma industry. News

> A panel from the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) has ruled out a complaint from a pharmacist that the artwork image for Boehringer Ingelheim's COPD drug Striverdi is misleading. More

> Boehringer Ingelheim's Ofev has won European approval as a treatment for idiopathic pulmonary fibrosis. Report

> Wales is providing access to Ariad Pharmaceutical's ($ARIA) Iclusig on its National Health Service. More

> BMG Pharma has signed an exclusive distribution agreement with Ferrer Internacional, granting it the rights to promote, sell and market its GelX for the Middle East, Eastern Europe, Russia and North Africa. Release

And Finally... The FDA has clarified the lines between wellness devices and regulated medical devices. More

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.